3 withdrawn. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Withdrawn 3 |
Follow Uremia: new trials by email Literature Review of Uremia trials Research Report on Uremia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Eculizumab to Cemdisiran Switch in aHUS cemdisiran, Placebos - Atypical Hemolytic Uremic Syndrome | Phase 2 | Withdrawn | Mario Negri Institute for Pharmacological Research | 2021-01-01 | 2021-03-10 | |
| A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome Cemdisiran - Atypical Hemolytic Uremic Syndrome | Phase 2 | Withdrawn | Alnylam Pharmaceuticals | 2017-09-19 | 2018-10-01 | |
| Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma Lycopene - Carcinoma, Transitional Cell | Phase 2 | Withdrawn | National Taiwan University Hospital | 80 | 2006-01-01 | 2008-09-26 |
Atypical Hemolytic Uremic Syndrome (2) · Carcinoma, Transitional Cell (1) · Disease Progression (1) · Hemolysis (1) · Renal Insufficiency (1) · Thrombocytopenia (1) · Thrombotic Microangiopathies (1)
Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Kidney Diseases (3) · Male Urogenital Diseases (3) · Urogenital Diseases (3) · Urologic Diseases (3) · Anemia (2) · Anemia, Hemolytic (2) · Blood Platelet Disorders (2) · Cytopenia (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Hemolytic-Uremic Syndrome (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
Lycopene (1)
Alnylam Pharmaceuticals (1) · Mario Negri Institute for Pharmacological Research (1) · National Taiwan University Hospital (1)
Bosnia and Herzegovina (1) · Canada (1) · Estonia (1) · Georgia (1) · Italy (1) · Latvia (1) · Lithuania (1) · Moldova (1) · North Macedonia (1) · Serbia (1) · Sweden (1) · Taiwan (1)
Nader Najafian, MD (1) · Yeong-Shiau Pu, MD, PhD (1)
2018 (1)